{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T16:58:35Z","timestamp":1785430715699,"version":"3.56.0"},"reference-count":33,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002402","name":"Sun Yat-sen University","doi-asserted-by":"publisher","award":["2019028"],"award-info":[{"award-number":["2019028"]}],"id":[{"id":"10.13039\/501100002402","id-type":"DOI","asserted-by":"publisher"}]},{"award":["2019028"],"award-info":[{"award-number":["2019028"]}],"id":[{"id":"https:\/\/ror.org\/0064kty71","id-type":"ROR","asserted-by":"publisher"}]},{"name":"Guangdong Province Basic and Applied Basic Research Fund","award":["2023A1515220150"],"award-info":[{"award-number":["2023A1515220150"]}]},{"name":"Guangdong Province Basic and Applied Basic Research Fund","award":["2024A1515220158"],"award-info":[{"award-number":["2024A1515220158"]}]},{"DOI":"10.13039\/100007452","name":"Wu Jieping Medical Foundation","doi-asserted-by":"publisher","award":["H2023053"],"award-info":[{"award-number":["H2023053"]}],"id":[{"id":"10.13039\/100007452","id-type":"DOI","asserted-by":"publisher"}]},{"award":["H2023053"],"award-info":[{"award-number":["H2023053"]}],"id":[{"id":"https:\/\/ror.org\/05dgwj702","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: Multiple myeloma (MM) is an incurable hematologic malignancy, and the majority of patients eventually relapse due to persistent myeloma cells. While minimal residual disease (MRD) reflects tumor burden, the host immune system also plays a crucial role in disease control. Our study aimed to evaluate MRD, complete blood count (CBC), and immune cell profiles in MM patients treated with bortezomib\/adriamycin\/dexamethasone (PAD) chemotherapy followed by autologous stem cell transplantation (ASCT) to determine their prognostic value and interplay. Objectives: This study aims to identify markers indicative of a favorable prognosis in MM patients. Methods: CBC data were collected from 93 MM patients at diagnosis, prior to ASCT, and 3 months post-ASCT. Immune cell profiles were assessed via flow cytometry using fresh peripheral blood samples from a subset of 33 prior to ASCT and 3 months post-ASCT. We subsequently investigated the associations between MRD status and prognosis, the predictive value of CBC, and the longitudinal changes in immune cell profiles and their correlation with clinical outcomes. Results: An increased frequency of negative immunomodulatory cell subsets and activated T lymphocytes prior to ASCT were associated with a poor prognosis. Conversely, lower levels of exhausted T lymphocytes, alongside higher levels of functional T cells and marginal zone B cells post-ASCT, predicted a favorable prognosis. Conclusions: Our study demonstrates that pre-ASCT immune status, post-ASCT immune reconstitution, and MRD status at 3 months post-ASCT are closely associated with clinical outcomes in MM patients. These findings underscore the critical importance of regular immune monitoring in the comprehensive management of MM.<\/jats:p>","DOI":"10.3390\/cancers18152389","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T10:38:41Z","timestamp":1784889521000},"page":"2389","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Prognostic Value of Combined Complete Blood Count and Immune Cell Profiling in Patients with Multiple Myeloma Treated with Chemotherapy Sequential Transplantation"],"prefix":"10.3390","volume":"18","author":[{"given":"Jiang","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Laboratory Medicine, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510080, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-6498-5595","authenticated-orcid":false,"given":"Yao","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510080, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yizhi","family":"Mao","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510080, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaoming","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510080, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengzhi","family":"Hong","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510080, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0636-9506","authenticated-orcid":false,"given":"Junxun","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510080, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Ouyang","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510080, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41572-024-00529-7","article-title":"Multiple myeloma","volume":"10","author":"Malard","year":"2024","journal-title":"Nat. Rev. Dis. Prim."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1002\/ajh.27422","article-title":"Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management","volume":"99","author":"Rajkumar","year":"2024","journal-title":"Am. J. Hematol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"5195","DOI":"10.1158\/1078-0432.CCR-21-1059","article-title":"Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration","volume":"27","author":"Anderson","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_4","first-page":"2049","article-title":"Role of minimal residual disease assessment in multiple myeloma","volume":"109","author":"Szalat","year":"2024","journal-title":"Haematologica"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1016\/j.clml.2019.09.622","article-title":"Minimal Residual Disease Status as a Surrogate Endpoint for Progression-free Survival in Newly Diagnosed Multiple Myeloma Studies: A Meta-analysis","volume":"20","author":"Ludwig","year":"2020","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1182\/bloodadvances.2020002037","article-title":"Clinical value of measurable residual disease testing for assessing depth, duration, and direction of response in multiple myeloma","volume":"4","author":"Wong","year":"2020","journal-title":"Blood Adv."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1186\/s13045-021-01162-7","article-title":"Prognostic and predictive biomarker developments in multiple myeloma","volume":"14","author":"Mynott","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e302","DOI":"10.1016\/S1470-2045(19)30309-2","article-title":"International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders","volume":"20","author":"Hillengass","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2681675","DOI":"10.1080\/14796694.2026.2681675","article-title":"Clinical implications and predictors of MRD resurgence in ASCT-eligible patients with NDMM: A real-world study in China","volume":"22","author":"Li","year":"2026","journal-title":"Future Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13045-022-01234-2","article-title":"Deciphering mechanisms of immune escape to inform immunotherapeutic strategies in multiple myeloma","volume":"15","author":"Swamydas","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e923716","DOI":"10.12659\/MSM.923716","article-title":"Peripheral Absolute Lymphocyte Count: An Economical and Clinical Available Immune-Related Prognostic Marker for Newly Diagnosed Multiple Myeloma","volume":"26","author":"Yang","year":"2020","journal-title":"Med. Sci. Monit."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"129","DOI":"10.4102\/ajlm.v10i1.1713","article-title":"Higher proportion of non-classical and intermediate monocytes in newly diagnosed multiple myeloma patients in Egypt: A possible prognostic marker","volume":"10","author":"Zahran","year":"2021","journal-title":"Afr. J. Lab. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1093\/carcin\/bgaa037","article-title":"Genotype-immunophenotype analysis reveals the immunogenomic subtype and prognosis of multiple myeloma","volume":"41","author":"Wang","year":"2020","journal-title":"Carcinogenesis"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1182\/bloodadvances.2017005447","article-title":"Immune signatures associated with improved progression-free and overall survival for myeloma patients treated with AHSCT","volume":"1","author":"Ho","year":"2017","journal-title":"Blood Adv."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Lin, J., Zhang, X., Zhao, Y., Luo, L., Yuan, H., and Zhong, L. (2026). Differential expression of immune activation markers in T cells from patients with multiple myeloma. Front. Oncol., 16.","DOI":"10.3389\/fonc.2026.1788729"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1038\/leu.2012.122","article-title":"EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols","volume":"26","author":"Kalina","year":"2012","journal-title":"Leukemia"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"107976","DOI":"10.1016\/j.dib.2022.107976","article-title":"Optimized gating strategy and supporting flow cytometry data for the determination of the Ki-67 proliferation index in the diagnosis of myelodysplastic syndrome","volume":"41","author":"Mestrum","year":"2022","journal-title":"Data Brief"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"5988","DOI":"10.1182\/bloodadvances.2020002827","article-title":"A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma","volume":"4","author":"Munshi","year":"2020","journal-title":"Blood Adv."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s41375-020-01012-4","article-title":"International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials","volume":"35","author":"Costa","year":"2021","journal-title":"Leukemia"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1080\/10428194.2016.1228930","article-title":"Minimal residual disease evaluation in autologous stem cell transplantation recipients with multiple myeloma","volume":"58","author":"Gupta","year":"2017","journal-title":"Leuk. Lymphoma"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"18792","DOI":"10.18632\/oncotarget.13320","article-title":"Elevated neutrophil-to-lymphocyte ratio and monocyte-to-lymphocyte ratio and decreased platelet-to-lymphocyte ratio are associated with poor prognosis in multiple myeloma","volume":"8","author":"Shi","year":"2017","journal-title":"Oncotarget"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e13359","DOI":"10.1111\/ctr.13359","article-title":"Can Neutrophil-to-Lymphocyte Ratio, Monocyte-to-Lymphocyte Ratio, and Platelet-to-Lymphocyte Ratio at Day +100 be used as a prognostic marker in Multiple Myeloma patients with autologous transplantation?","volume":"32","author":"Acar","year":"2018","journal-title":"Clin. Transplant."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jcyt.2019.10.008","article-title":"Low baseline platelet count predicts poor response to plerixafor in patients with multiple myeloma undergoing autologous stem cell mobilization","volume":"22","author":"Bakeer","year":"2020","journal-title":"Cytotherapy"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1007\/s00277-020-04092-5","article-title":"Prognostic value of pretreatment neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios in multiple myeloma patients treated with thalidomide-based regimen","volume":"99","author":"Mlak","year":"2020","journal-title":"Ann. Hematol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"6960","DOI":"10.1038\/s41467-021-26951-z","article-title":"Subclone-specific microenvironmental impact and drug response in refractory multiple myeloma revealed by single-cell transcriptomics","volume":"12","author":"Tirier","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Zaghi, E., Calvi, M., Di Vito, C., and Mavilio, D. (2019). Innate Immune Responses in the Outcome of Haploidentical Hematopoietic Stem Cell Transplantation to Cure Hematologic Malignancies. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.02794"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Verheye, E., Bravo Melgar, J., Deschoemaeker, S., Raes, G., Maes, A., De Bruyne, E., Menu, E., Vanderkerken, K., Laoui, D., and De Veirman, K. (2022). Dendritic Cell-Based Immunotherapy in Multiple Myeloma: Challenges, Opportunities, and Future Directions. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23020904"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.4110\/in.2020.20.e5","article-title":"Heterogeneity of Human gammadelta T Cells and Their Role in Cancer Immunity","volume":"20","author":"Lee","year":"2020","journal-title":"Immune Netw."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Suzuki, K., Nishiwaki, K., and Yano, S. (2021). Treatment Strategy for Multiple Myeloma to Improve Immunological Environment and Maintain MRD Negativity. Cancers, 13.","DOI":"10.3390\/cancers13194867"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1158\/2326-6066.CIR-15-0055","article-title":"T-cell Exhaustion in Multiple Myeloma Relapse after Autotransplant: Optimal Timing of Immunotherapy","volume":"4","author":"Chung","year":"2016","journal-title":"Cancer Immunol. Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e004012","DOI":"10.1136\/jitc-2021-004012","article-title":"CD8+ PD-1+ to CD4+ PD-1+ ratio (PERLS) is associated with prognosis of patients with advanced NSCLC treated with PD-(L)1 blockers","volume":"10","author":"Duchemann","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Zhaoyun, L., and Rong, F. (2021). Predictive Role of Immune Profiling for Survival of Multiple Myeloma Patients. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.663748"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"eabf7470","DOI":"10.1126\/science.abf7470","article-title":"Marginal zone B cells acquire dendritic cell functions by trogocytosis","volume":"375","author":"Schriek","year":"2022","journal-title":"Science"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/15\/2389\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T10:49:19Z","timestamp":1784890159000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/15\/2389"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,24]]},"references-count":33,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["cancers18152389"],"URL":"https:\/\/doi.org\/10.3390\/cancers18152389","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,24]]}}}